<DOC>
	<DOCNO>NCT01536600</DOCNO>
	<brief_summary>This study conduct Africa , Asia Europe . The aim study investigate biphasic insulin aspart 30 ( NovoMixÂ® 30 ) alone combination oral hypoglycaemic agent ( OHA ) type 2 diabetes management routine clinical practice .</brief_summary>
	<brief_title>Observational Study Biphasic Insulin Aspart 30 Alone Combination With Oral Hypoglycaemic Agents Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects type 2 diabetes whose glycaemia optimally control current therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>